Relay Therapeutics, Inc. (RLAY) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$16.53

From 52W high−17.64%

Volume1.75M

Market cap$3.75B

P/E (TTM)—

P/S (TTM)361.8x

Div yield—

Key dataOct 19, 2026

Open

$16.53

From 52W high

−17.64%

Volume

1.75M

Market cap

$3.75B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−10.1x

P/E (TTM)

—

RSI (14)

41.1

MomentumView details →

1D Return

+4.98%

YTD Return

+99.61%

SummaryUpdated Jun 1, 2026

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company founded in 2015 and headquartered in Cambridge, Massachusetts. Originally incorporated as Allostery, Inc., the company changed its name to Relay Therapeutics in December 2015 and went public in July 2020. Relay focuses on transforming drug discovery through computational approaches, with an emphasis on developing small molecule therapeutics for targeted oncology and genetic diseases.

Ask drillr about Relay Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−10.1x

EV/Sales

276.8x

P/S (TTM)

361.8x

P/B (TTM)

4.2x

ProfitabilityView details →

Gross Margin

−566.59%

Net Margin

−2763.64%

EBITDA Margin

−2742.28%

ROE (TTM)

−32.14%

ROA (TTM)

−29.57%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

+23.86%

EPS YoY

+19.49%

FCF YoY

+19.02%

Revenue CAGR 3Y

+123.20%

EPS CAGR 3Y

+31.78%

EBITDA YoY

+12.37%

MomentumView details →

1D Return

+4.98%

YTD Return

+99.61%

1Y Return

+136.51%

RSI (14)

41.1

vs 50D SMA

−10.11%

vs 200D SMA

+16.32%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

18.27x

Quick Ratio

18.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.41

EPS Surprise

−4.84%

Beats (12Q)

6/12

Next Q EPS Est

−$0.37

Avg Surprise (4Q)

−3.98%

Rev Surprise

−63.54%

Financials snapshotView financials →

Revenue (TTM)

10.35M

Net Income (TTM)

−286.04M

Op. CF (TTM)

−212.21M

Next earningsNov 5, 2026 →

Latest newsMore news →

Relay Therapeutics, Inc. reported a second-quarter loss of $0.41 per share, in line with the Zacks Consensus Estimate and unchanged from the year-ago quarter.74d ago

Similar companies

TransThera Sciences (Nanjing) Inc.02617.HK Adaptive Biotechnologies CorporationADPT Mirxes Holding Company Limited02629.HK Telix Pharmaceuticals LimitedTLX Catalyst Pharmaceuticals, Inc.CPRX AbCellera Biologics Inc.ABCL Find similar companies →

Latest newsMore news →

Relay Therapeutics, Inc. reported a second-quarter loss of $0.41 per share, in line with the Zacks Consensus Estimate and unchanged from the year-ago quarter.74d ago